Search

Displaying results 3101 - 3110 of 10000 in total
  1. Drug

    Ebola Zaire vaccine (live, attenuated)

    go.drugbank.com/drugs/DB15595
    ApprovedInvestigational

    [L10866] In non-human primate clinical trials, the vaccine was effective in inducing an immune response against the Ebola viruses. … Ervebo consists of an envelope glycoprotein of the Zaire ebolavirus (Kikwit 1995 strain) fused into a vesicular stomatitis virus (VSV) backbone.

  2. Drug

    Eritoran

    go.drugbank.com/drugs/DB04933
    Investigational

    Eritoran is a structural analogue of the lipid A portion of lipopolysaccharide (LPS). It is being developed by Eisai Research Institute of Boston for the treatment of severe sepsis.

    Categories: Toll-Like Receptor 4, antagonists & inhibitors
  3. Drug

    Ruxolitinib

    go.drugbank.com/drugs/DB08877
    ApprovedInvestigational

    Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. … [A229708] In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in

  4. Drug

    Cresol

    go.drugbank.com/drugs/DB11143
    Approved

    Cresol is a hydroxytoluene that can be extracted naturally from coal tar or made synthetically. Pure cresol is a mixture of ortho-, meta-, and para- isomers. … Ingestion of cresol induces toxicity in humans and can lead to burning of the mouth and throat, abdominal pain, and/or vomiting.

  5. Drug

    Echothiophate

    go.drugbank.com/drugs/DB01057
    ApprovedInvestigational

    A potent, long-acting irreversible cholinesterase inhibitor used as an ocular hypertensive in the treatment of glaucoma. Occasionally used for accomodative esotropia.

  6. Drug

    Filgotinib

    go.drugbank.com/drugs/DB14845
    ApprovedInvestigational

    Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases. … In contrast, the newly approved filgotinib is a highly selective JAK1 inhibitor.

  7. Drug

    Bifeprunox

    go.drugbank.com/drugs/DB04888
    Investigational

    Bifeprunox is a novel atypical antipsychotic agent which, along with SLV313, [aripiprazole] and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.

  8. Drug

    Quizartinib

    go.drugbank.com/drugs/DB12874
    ApprovedInvestigational

    Quizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug developed specifically targeting FLT3, as other agents with FLT3 inhibition activities were investigated … with other targets in mind.

  9. Drug

    Molsidomine

    go.drugbank.com/drugs/DB09282
    ApprovedWithdrawn

    Molsidomine is an orally active, long-acting vasodilator, which belongs to the class of medications known as syndnones. … Interestingly, it is being studied as being a preventive measure in cerebral infarction [A31932].

    Categories: Vasodilators Used in Cardiac Diseases
  10. Drug

    Iloperidone

    go.drugbank.com/drugs/DB04946
    ApprovedInvestigational

    Iloperidone is a benzisoxazole [A263557] and an atypical antipsychotic agent that was first approved by the FDA on May 6, 2009. … [A3024] It is considered to be a second-generation antipsychotic drug [A263552] with multiple receptor binding profile, although it shows high affinity towards 5-HT<sub>2A</sub> and dopamine D2 receptors

    Categories: Adrenergic alpha-1 Receptor Antagonists, Dopamine D2 Receptor Antagonists